具有过敏史的患者患有皮肤黑色素瘤的数量比没有过敏史的患者少:一项在496名患有皮肤癌风险的患者中进行的横断面研究。
Patients with a history of atopy have fewer cutaneous melanomas than those without atopy: a cross-sectional study in 496 patients at risk of skin cancers.
发表日期:2023 Feb 28
作者:
Jenni Komulainen, Hanna Siiskonen, Salla Haimakainen, Emilia Kanasuo, Rauno J Harvima, Ilkka T Harvima
来源:
Pigment Cell & Melanoma Research
摘要:
过敏和皮肤癌之间的关系可能与保护性免疫反应的刺激有关,例如通过自身免疫球蛋白E (IgE),或者与慢性炎症引起的癌症易感性有关。这项研究的目的是调查过去或现在的过敏疾病是否与皮肤光损伤、色素细胞痣和皮肤癌相关联。为此,对有任何类型皮肤癌风险的成年受试者(年龄在21-79岁之间,男性250人,女性246人,94人免疫抑制)进行了检查,包括皮肤和非皮肤部位上过去或现在的恶性肿瘤、光损伤、痣、过去或现在皮肤或黏膜部位的过敏性疾病以及可能的其他癌症相关因素。没有发现过敏和光损伤、角质细胞癌或痣数量之间的关联。相反,在过敏症候群中,黑色素瘤的受试者较少(14.6%)比非过敏症候群中的受试者(22.2%)(P = 0.044);过敏者皮肤癌的风险级别比非过敏者低。在所有受试者中,过敏受试者黑色素瘤的多元逻辑回归比值(OR)为0.583(P=0.046;95%置信区间,0.343-0.990),但在免疫能力正常的受试者中,风险降低仅限于黏膜部位的过敏受试者(OR,0.417;P=0.020)。此外,在过敏症候群中,非皮肤部位的恶性肿瘤受试者较少(8.8%)比非过敏症候群中的受试者(15.7%)(P = 0.031)。没有发现血清总IgE与皮肤癌、光损伤、痣或非皮肤部位的恶性肿瘤之间的关联。总之,过敏,特别是黏膜部位的过敏,与患有黑色素瘤的受试者比例较低相关。 版权所有© 2023 Wolters Kluwer Health,Inc.保留所有权利。
The connection between atopy and skin cancers may be related to the stimulation of protective immune response, for example, through autoreactive immunoglobulin-E (IgE), or to the predisposition to carcinogenesis through chronic inflammation. The aim of this study was to investigate whether a past or present atopic disorder is associated with cutaneous photodamage, pigment cell nevi and skin cancers. For this, adult subjects at risk of any type of skin cancer (aged 21-79 years, 250 males, 246 females, 94 with immunosuppression) were examined for past or present malignancies in skin and extracutaneous site (ECS), photodamage, nevi, past or present atopic disorder in skin or mucus membranes, and possible other cancer-related factors. No association between atopy and photodamage, keratinocyte carcinomas or nevus count was found. Instead, there were fewer subjects with melanoma in 171 atopic (14.6%) than in 325 nonatopic subjects (22.2%) (P = 0.044), and the investigator-estimated risk class of skin cancers was lower in atopic than nonatopic subjects. In all subjects, the multivariate odds ratio (OR) for melanoma was 0.583 (P = 0.046; 95% confidence interval, 0.343-0.990) in atopic subjects, but in immunocompetent subjects, the reduced risk was confined to mucus membrane atopy (OR, 0.417; P = 0.020). Also, there were fewer subjects with malignancy in ECS in atopic (8.8%) than nonatopic subjects (15.7%) (P = 0.031). No association between serum total IgE and skin cancers, photodamage, nevi or malignancies in ECS was found. In conclusion, the atopy, especially mucus membrane atopy, is associated with lower percentages of subjects with a history of melanoma.Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.